Latest data nudges Novartis closer to fourth Cosentyx indication

2 October 2019

Swiss pharma giant Novartis (NOVN: VX) has presented additional data from the Phase III PREVENT trial on the use of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis (nr-axSpA).

The ongoing study met its primary endpoint at Week 52, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo.

Positive 16-week PREVENT data were a nnounced mid-September and submitted to European Medicines Agency for approval in nr-axSp. These results add to the five-years of clinical data supporting the long-term efficacy and safety of Cosentyx across ankylosing spondylitis, psoriatic arthritis and psoriasis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK